A potential blood cancer treatment from drugmakers AbbVie and Bristol-Myers Squibb has been named a “breakthrough therapy” by the Food and Drug Administration, a designation designed to speed up the drug’s testing and approval process.
The drug, elotuzumab, received the designation for use in combination with another treatment, lenalidomide, and the steroid dexamethasone for treating multiple myeloma patients who have already tried other therapies.
— UPCOMING EVENTS —
5/22 9:00 am – 4:00 pm in New Haven
Biotech Entrepreneur Bootcamp – daylong workshop … more
CURE annual meeting and BioHaven panel discussion: “Growing Connecticut’s Bioscience Community: Supporting Ideas, Creating Value” … more